Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
調査の概要
詳細な説明
This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Hubert Chen, MD
- 電話番号:8587044660
- メール:clinicaltrials@vikingtherapeutics.com
研究場所
-
-
Arizona
-
Tucson、Arizona、アメリカ、85741
- 募集
- Viking Clinical Site #2020
-
コンタクト:
- 電話番号:520-333-4515
-
-
California
-
Lake Forest、California、アメリカ、92630
- 募集
- Viking Clinical Site #2015
-
コンタクト:
- 電話番号:714-550-9990
-
-
Florida
-
Ocoee、Florida、アメリカ、34761
- 募集
- Viking Clinical Site #2059
-
コンタクト:
- 電話番号:407-654-2724
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30329
- 募集
- Viking Clinical Site #2013
-
コンタクト:
- 電話番号:404-920-6201
-
-
Indiana
-
Evansville、Indiana、アメリカ、47714
- 募集
- Viking Clinical Site #2001
-
コンタクト:
- 電話番号:812-477-2760
-
Indianapolis、Indiana、アメリカ、46202
- 募集
- Viking Clinical Site #2046
-
コンタクト:
- 電話番号:504-336-2667
-
Valparaiso、Indiana、アメリカ、46383
- 募集
- Viking Clinical Site #2009
-
コンタクト:
- 電話番号:219-464-8302
-
-
Minnesota
-
Richfield、Minnesota、アメリカ、55423
- 募集
- Viking Clinical Site #2004
-
コンタクト:
- 電話番号:952-922-7000
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39206
- 募集
- Viking Clinical Site #2029
-
コンタクト:
- 電話番号:770-330-4157
-
-
Missouri
-
Springfield、Missouri、アメリカ、65807
- 募集
- Viking Clinical Site #2028
-
コンタクト:
- 電話番号:504-338-0917
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87107
- 募集
- Viking Clinical Site #2052
-
コンタクト:
- 電話番号:505-243-1627
-
-
New York
-
Binghamton、New York、アメリカ、13905
- 募集
- Viking Clinical Site #2039
-
コンタクト:
- 電話番号:607-800-5777
-
-
Oregon
-
Medford、Oregon、アメリカ、97504
- 募集
- Viking Clinical Site #2023
-
コンタクト:
- 電話番号:541-858-1018
-
-
Rhode Island
-
East Greenwich、Rhode Island、アメリカ、02818
- 募集
- Viking Clinical Site #2002
-
コンタクト:
- 電話番号:401-739-9350
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29407
- 募集
- Viking Clinical Site #2044
-
コンタクト:
- 電話番号:843-432-2477
-
-
Tennessee
-
Hendersonville、Tennessee、アメリカ、37075
- 募集
- Viking Clinical Site #2030
-
コンタクト:
- 電話番号:504-339-0917
-
-
Texas
-
Abilene、Texas、アメリカ、79606
- 募集
- Viking Clinical Site #2031
-
コンタクト:
- 電話番号:325-400-1150
-
-
Washington
-
Seattle、Washington、アメリカ、98105
- 募集
- Viking Clinical Site #2011
-
コンタクト:
- 電話番号:206-536-3030
-
Spokane、Washington、アメリカ、99218
- 募集
- Viking Clinical Site #2042
-
コンタクト:
- 電話番号:509-505-6227
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥18 years of age at the time of signing the informed consent.
- Body mass index (BMI) ≥ 27 kg/m2
- Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.
Exclusion Criteria:
-
History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
-
Self-reported body weight change of 5% or more within 3 months of screening
-
Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed >1 year prior to screening)
-
Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
-
Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)
-
Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening
• Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG < 54 mg/dL.
-
Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
-
Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6.
-
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
-
History of acute or chronic pancreatitis
-
Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:Placebo Assignment
Placebo comparator orally once daily |
Placebo comparator administered orally once daily |
|
実験的:Active Assignment (Dose 1)
VK2735 Dose level 1 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
実験的:Active Assignment (Dose 2)
VK2735 Dose level 2 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
実験的:Active Assignment (Dose 3)
VK2735 Dose level 3 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily
時間枠:68 weeks
|
To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 |
68 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。